Eti Mitrany
Direktor/Vorstandsmitglied bei BRAINSWAY LTD.
Vermögen: - $ am 30.04.2024
Profil
Eti Mitrany is currently an Independent Director at Brainsway Ltd.
and a Director at Trioxnano Ltd.
Previously, she worked at Teva Pharmaceutical Industries Ltd.
for 25 years, where she held the position of Senior Vice President-Head of Economic from 2012 to 2020.
She also served as the Global Chief Financial Officer at Copaxone.
In 2021-2022, she was the Chief Financial Officer & Head-Corporate Strategy at CytoReason Ltd.
Ms. Mitrany received her undergraduate degree in 1994 and her MBA in 1997, both from Tel-Aviv University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BRAINSWAY LTD
-.--% | 18.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Eti Mitrany
| Unternehmen | Position | Beginn |
|---|---|---|
| BRAINSWAY LTD. | Direktor/Vorstandsmitglied | 05.06.2016 |
| Trioxnano Ltd. | Direktor/Vorstandsmitglied | 01.01.2023 |
Ehemalige bekannte Positionen von Eti Mitrany
| Unternehmen | Position | Ende |
|---|---|---|
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Finanzdirektor/CFO | 01.12.2022 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01.01.2020 |
| Copaxone | Finanzdirektor/CFO | - |
Ausbildung von Eti Mitrany
| Tel-Aviv University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| BRAINSWAY LTD. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Trioxnano Ltd. | |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Technology Services |
| Copaxone |
